Evaxion (EVAX) CSO Birgitte Rono details extensive warrant holdings
Rhea-AI Filing Summary
Evaxion A/S Chief Scientific Officer Birgitte Rono filed an amended Form 3 to update her equity holdings. The filing lists multiple warrant positions over Evaxion ordinary shares, including warrants exercisable at prices ranging from 0.07 to 5.38 with expirations extending to 2036-12-31. One warrant series relates to a private placement that closed on 2023-12-21, and certain awards vest monthly over 36 months from their initial exercise dates. The amendment also shows direct ownership of 36,765 ordinary shares, giving investors a clearer picture of her current stake.
Positive
- None.
Negative
- None.
Insider Trade Summary
11 transactions reported
Mixed
11 txns
Insider
Rono Birgitte
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Warrants — 323,641 shares (Direct);
Ordinary Shares — 36,765 shares (Direct)
Footnotes (2)
- F1. Warrants pursuant to private placement that closed 12/21/2023.
- F2. Vesting is 1/36 per month over 36 months from the initial exercise date indicated.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Evaxion A/S (EVAX) Chief Scientific Officer Birgitte Rono report in this Form 3/A?
She reports updated holdings of warrants and ordinary shares in Evaxion A/S. The filing details several warrant series over ordinary shares plus direct ownership of 36,765 ordinary shares, clarifying her current equity stake as an officer.
What warrant positions are disclosed for Birgitte Rono in Evaxion (EVAX) according to the Form 3/A?
The filing lists multiple warrant holdings over Evaxion ordinary shares, with exercise prices from 0.07 to 5.38 and expirations out to 2036-12-31. Each series specifies the underlying share amount and direct ownership status.
Is any of Birgitte Rono’s Evaxion (EVAX) warrant position tied to a private placement?
Yes. A warrant position referencing 36,765 underlying ordinary shares is noted as issued pursuant to a private placement that closed on 2023-12-21. This footnote links that specific warrant series to the prior financing event.
How do Birgitte Rono’s Evaxion (EVAX) warrants vest according to the Form 3/A footnotes?
The footnotes state that certain awards vest at 1/36 per month over 36 months from the initial exercise date. This means vesting is gradual, with equal monthly portions becoming exercisable across the three-year schedule.